

India : India Responsive COVID-19 Vaccines for Recovery

1. Project Information

Project ID:	P000564	Instrument ID:	L0564A
Member:	India	Region:	Southern Asia
Sector:	CRF-Public Health	Sub-sector:	N/A
Instrument type:	<input checked="" type="checkbox"/> Loan:402.81 US Dollar million <input type="checkbox"/> Guarantee	Lead Co-financier(s):	Asian Development Bank
ES category:	C	Borrowing Entity:	Ministry of Finance, India
Implementing Entity:	Ministry of Health and Family Welfare, India		
Project Team Leader:	Ankur Agrawal		
Responsible DG:	Rajat Misra		
Responsible Department:	INF1		
Project Team Members:	Yang Shuai, OSD - Environment & Social Development Specialist; Rabindra Shah, OSD - Procurement Specialist; Yogesh Malla, OSD - Financial Management Specialist; Hari Bhaskar, Team Member; Christopher Damandl, Project Counsel; Aditi Khosla, Alternate Counsel; Jinghui Li, Project admin		
Completed Site Visits by AIIB:			
Planned Site Visits by AIIB:			
Current Red Flags Assigned:	0		
Current Monitoring Regime:	Regular Monitoring		
Previous Red Flags Assigned:	0		
Previous Red Flags Assigned Date:	2022/12		

2. Project Summary and Objectives

The objective of the Project is to vaccinate eligible populations against COVID-19 in the selected states of India (project states).

The Project will support the procurement of safe and effective vaccines against COVID-19. The project has been co-financed with the Asian Development Bank (ADB) under the rapid response component of ADB's Asia Pacific Vaccine Access Facility (APVAX).

The total Project cost is USD2.058 billion, for which AIIB finances USD500 million (24.30 percent), ADB finances USD1.5 billion (72.89 percent) and the Government of India (GoI) finances the remaining USD57.77 million (2.81 percent). The loan proceeds from AIIB and ADB will finance expenditures relating to the procurement of COVID-19 vaccines that meet the APVAX eligibility criteria. The GoI fund will cover financial charges during implementation, including interest, commitment charges and front-end fee. The GoI will also provide in-kind contributions in the

form of counterpart staff, logistics, cold chain infrastructure, and other facilities.

The Project is expected to procure at least 667 million doses of vaccines, which will be administered to a target population by 2024 in accordance with the current National Deployment Vaccine Plan (NDVP) for COVID-19 vaccines and any subsequent guidelines. The Project is to benefit at least 317 million people.

3. Key Dates

Approval:	Jan. 20, 2022	Signing:	Jan. 21, 2022
Effective:	Feb. 10, 2022	Restructured (if any):	Mar. 29, 2023
Orig. Closing:	Jun. 30, 2025	Rev. Closing (if any):	

4. Disbursement Summary (USD million)

Contract Awarded:		Cancellation (if any):	97.19
Disbursed:	398.23	Most recent disbursement (amount/date):	25.94/Dec. 27, 2022
Undisbursed:	4.58	Disbursement Ratio (%) ¹ :	98.86

5. Project Implementation Update

During the reporting period, a loan amount of USD97.19 million has been cancelled upon the request of the borrower. With this, the undisbursed loan is only about 1%. The entire financing has been towards the procurement of vaccines from two manufacturers - Serum Institute of India and Bharat Biotech International Limited.

Components	Physical Progress	Environmental & Social Compliance	Procurement
Procurement of eligible COVID-19 vaccines	A total of 526.51 million doses of vaccine have been procured under the project utilizing AIIB and ADB loan.	Under ADB's Safeguard Policy Statement (SPS), the project has been categorized as C for Environment, Involuntary Resettlement, and Indigenous Peoples on the basis that no adverse ES impacts are expected. No standalone safeguards monitoring report is required since the project is categorized C for all E&S aspects. However, according to the Updated Project Administration Manual, the progress report is expected to document and assess the COVID-19 immunization waste management system's adequacy,	All vaccine procurement contracts have been accomplished under the scope of AIIB financing. No further procurement contracts are due under AIIB's scope. Two manufactures were selected for manufacture and supply of vaccines and have been supplying the vaccines.

¹ Disbursement Ratio is defined as the volume (e.g. the dollar amount) of total disbursed amount as a percentage of the net committed volume.

		<p>quality of performance and corrective actions planned to improve its effectiveness, as needed. As a follow up action, ADB has granted USD1 million under APVAX as Technical Assistance (TA) to WHO to support the vaccination-related bio-medical waste management (BMWM) at national and state level. Constraints/Gaps at national level have been identified and are to be addressed, including the shortfall of intra-institutional capacity for BMWM in healthcare facilities. Progress has been made by i) developing standard operating procedures and various materials for dissemination, ii) capacity building of over 2,000 healthcare and frontline workers (40% women) and 200 civil society organizations and nongovernment organizations; iii) Demonstrating best practice examples through hand-holding support in 10 vaccination centers in three selected States including Delhi, Rajasthan and Tamil Nadu; iv) Developing guidance on improved BMW disposal practices as well as v) sharing findings widely through webinars for possible scaling up and adoption across other States. AIIB will continue to work closely with ADB to monitor the progress and report back milestones.</p>	
--	--	---	--

Financial Management:

As per the Financial Management Action Plan, an internal audit by the team of Chief Controller of Accounts, MoHFW for the year FY2021-22 has been conducted and no outstanding actions were reported. The audited project financial statement for FY21-22 has been overdue since September 30, 2022. It has been informed that the audit for FY2021-22 and for FY2022-23 will be undertaken simultaneously and has been initiated.

6. Status of the Grievance Redress Mechanism (GRM)

MOHFW has been operating a toll free 24x7 national helpline '1075' and another helpline (011-23978046) for addressing queries related to the COVID- 19 pandemic, vaccine rollout and the Co-WIN software. In addition to 1075, a technical helpline (0120-4473222) has been established to specifically handle Co-WIN software-related queries. Any technical issue which is not resolved by 1075 is directed to the Technical Helpline for resolution. MOHFW has also created an email ID (ncov2019@gov.in) for addressing COVID-19 related queries and grievances in addition to providing a repository of state COVID-19 helplines and website links for relevant resources, on its website - <https://www.mohfw.gov.in/>. State 104 helplines have been augmented to address queries on COVID-19 vaccination including grievance redressal related to vaccination process as well as linking to concerned facilities for

management of any adverse event. As per guidelines, all grievances are to be reviewed at regular intervals at the level of state task force, district task force, urban task force, and block task force.

7. Results Monitoring (please refer to the full RMF, which can be found on the last page of this PIMR)

Results have been achieved proportionate to the loan disbursement

Remarks:

Project Indicators	Objective	Indicator level	Unit Measure	Cumulative Target Values												Frequency	Responsibility	Comments	
				Baseline		2021		2022		2023		2024		End Target					
				Year	Value	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Year	Target				Actual
At least 317 million targeted people (at least 47.5% women) vaccinated with at least two doses against COVID-19 in project states.	Project	Text	2021							263.2 million					2024	317 million, 47.5% of them women			
By 2024, at least 667 million doses of COVID-19 vaccine procured and delivered to the project states.	Project	Number	2021							526.51 million					2024	667 million doses			

Project Indicators	Intermediate	Indicator level	Unit of Measure	Cumulative Target Values												Frequency	Responsibility	Comments	
				Baseline		2021		2022		2023		2024		End Target					
				Year	Value	Target	Actual	Target	Actual	Target	Actual	Target	Actual	Year	Target				Actual